» Articles » PMID: 16301374

Distribution of Type IV Collagen in the Cochlea in Alport Syndrome

Overview
Date 2005 Nov 23
PMID 16301374
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the distribution of alpha1, alpha3, and alpha5 chains of type IV collagen in the cochlea in Alport syndrome.

Design: Case-control study.

Patients: Two patients with sensorineural hearing loss due to Alport syndrome. Both patients had known mutations in the COL4A5 gene.

Main Outcome Measures: Immunostaining was used to study the distribution of type IV collagen (alpha1, alpha3, and alpha5 chains) within the cochlea. Immunostaining was also performed in the cochlear tissues of an unaffected individual used as a control.

Results: In the control ear, alpha1 staining was observed in the basement membrane overlying the basilar membrane, in the basement membrane of cochlear blood vessels and Schwann cells, and within the spiral limbus. In the control ear, we also observed strong staining for alpha3 and alpha5 chains in the basement membrane overlying the basilar membrane and within the spiral ligament. In both cases with Alport syndrome, no immunostaining was observed for alpha3 or alpha5 chains within the cochlea, whereas alpha1 staining was present in locations similar to that seen in the control ear.

Conclusions: The results indicate that isotype switching does not occur within the cochlea in Alport syndrome. The results are also consistent with the hypothesis that the sensorineural hearing loss in Alport syndrome may be due to alterations in cochlear micromechanics and/or dysfunction of the spiral ligament.

Citing Articles

Investigation of exon skipping therapy in kidney organoids from Alport syndrome patients derived iPSCs.

Yabuuchi K, Horinouchi T, Yamamura T, Nozu K, Takasato M Genes Cells. 2024; 29(12):1118-1130.

PMID: 39435529 PMC: 11609602. DOI: 10.1111/gtc.13170.


Unraveling the Genetic Basis of Combined Deafness and Male Infertility Phenotypes through High-Throughput Sequencing in a Unique Cohort from South India.

Margret J, Jayasankaran C, Amritkumar P, Azaiez H, Srisailapathy C Adv Genet (Hoboken). 2024; 5(2):2300206.

PMID: 38884051 PMC: 11170077. DOI: 10.1002/ggn2.202300206.


Genotype-Phenotype Correlations in Alport Syndrome-A Single-Center Experience.

Lujinschi S, Sorohan B, Obrisca B, Vrabie A, Lupusoru G, Achim C Genes (Basel). 2024; 15(5).

PMID: 38790222 PMC: 11121304. DOI: 10.3390/genes15050593.


Shared features in ear and kidney development - implications for oto-renal syndromes.

Wang S, Streit A Dis Model Mech. 2024; 17(2).

PMID: 38353121 PMC: 10886756. DOI: 10.1242/dmm.050447.


Alport Syndrome: Clinical Spectrum and Therapeutic Advances.

De Gregorio V, Caparali E, Shojaei A, Ricardo S, Barua M Kidney Med. 2023; 5(5):100631.

PMID: 37122389 PMC: 10131117. DOI: 10.1016/j.xkme.2023.100631.